US 11851481
Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
granted A61KA61K2039/505A61K2039/543
Quick answer
US patent 11851481 (Treatment of central nervous system disorders by intranasal administration of immunoglobulin g) held by Takeda Pharmaceutical Company Limited expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/543, A61K31/198, A61K31/401